Bispecific antibodies: A new era of treatment for multiple myeloma
Zhou X, Einsele H, Danhof S (2020)
Publication Type: Journal article, Review article
Publication year: 2020
Journal
Book Volume: 9
Pages Range: 1-14
Article Number: 2166
Journal Issue: 7
DOI: 10.3390/jcm9072166
Abstract
Despite the introduction of novel agents such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplant, multiple myeloma (MM) largely remains an incurable disease. In recent years, monoclonal antibody-based treatment strategies have been developed to target specific surface antigens on MM cells. Treatment with bispecific antibodies (bsAbs) is an immunotherapeutic strategy that leads to an enhanced interaction between MM cells and immune effector cells, e.g., T-cells and natural killer cells. With the immune synapse built by bsAbs, the elimination of MM cells can be facilitated. To date, bsAbs have demonstrated encouraging results in preclinical studies, and clinical trials evaluating bsAbs in patients with MM are ongoing. Early clinical data show the promising efficacy of bsAbs in relapsed/refractory MM. Together with chimeric antigen receptor-modified (CAR)-T-cells, bsAbs represent a new dimension of precision medicine. In this review, we provide an overview of rationale, current clinical development, resistance mechanisms, and future directions of bsAbs in MM.
Involved external institutions
Germany (DE)How to cite
APA:
Zhou, X., Einsele, H., & Danhof, S. (2020). Bispecific antibodies: A new era of treatment for multiple myeloma. Journal of Clinical Medicine, 9(7), 1-14. https://doi.org/10.3390/jcm9072166
MLA:
Zhou, Xiang, Hermann Einsele, and Sophia Danhof. "Bispecific antibodies: A new era of treatment for multiple myeloma." Journal of Clinical Medicine 9.7 (2020): 1-14.
BibTeX: Download